PMID- 29805594
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 15
IP  - 6
DP  - 2018 Jun
TI  - Patient-derived tumor xenografts of lung squamous cell carcinoma alter long 
      non-coding RNA profile but not responsiveness to cisplatin.
PG  - 8589-8603
LID - 10.3892/ol.2018.8401 [doi]
AB  - Lung squamous cell carcinoma (LSCC), the second most common type of lung cancer, 
      has received limited attention. Patient-derived tumor xenografts (PDTXs) are 
      useful preclinical models to reproduce the diverse heterogeneity of cancer, but 
      it is important to identify potential variations during their establishment. A 
      total of 18 PDTXs were established from 37 the surgical specimens and 16 were 
      serially passaged to third generation. Second- and third-generation xenografts 
      had a faster growth rate in mice. The tumor implantation success rate was 
      associated with poorer differentiation, larger tumor volume and higher expression 
      of Ki-67. The xenografts largely retained histological and key immunophenotypic 
      features (including p53, p63, cytokeratin5/6, and E-cadherin). However, increased 
      Ki-67 expression was identified in partial xenografts. Long non-coding RNA 
      (lncRNA) and mRNA expression in third-generation xenografts differed from that of 
      matched primary tumors. Gene Ontology and pathway analysis showed that mRNAs 
      involved in cell cycle, and metabolism regulation were generally upregulated in 
      xenografts, while those associated with immune responses were typically 
      downregulated. Furthermore, the responses of xenografts to cisplatin were 
      consistent with clinical outcome. In the present study, PDTXs of SCC were 
      successfully established, and closely resembled their original tumor regarding 
      their immunophenotype and response to cisplatin. Overall, PDTXS of LSCC altered 
      the lncRNA profile and increased the proliferative activity of cancer cells, 
      whilst retaining responsiveness to cisplatin.
FAU - Lu, Dapeng
AU  - Lu D
AD  - Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui 230001, P.R. China.
FAU - Luo, Peng
AU  - Luo P
AD  - Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui 230001, P.R. China.
FAU - Zhang, Ju
AU  - Zhang J
AD  - Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui 230001, P.R. China.
FAU - Ye, Yuanyuan
AU  - Ye Y
AD  - School of Life Sciences, University of Science and Technology of China, Hefei, 
      Anhui 230026, P.R. China.
FAU - Wang, Qi
AU  - Wang Q
AD  - Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui 230001, P.R. China.
FAU - Li, Ming
AU  - Li M
AD  - Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui 230001, P.R. China.
FAU - Zhou, Hangcheng
AU  - Zhou H
AD  - Department of Pathology, Affiliated Provincial Hospital of Anhui Medical 
      University, Hefei, Anhui 230001, P.R. China.
FAU - Xie, Mingran
AU  - Xie M
AD  - Department of Thoracic Surgery, Affiliated Provincial Hospital of Anhui Medical 
      University, Hefei, Anhui 230001, P.R. China.
FAU - Wang, Baolong
AU  - Wang B
AD  - Department of Clinical Laboratory, Affiliated Provincial Hospital of Anhui 
      Medical University, Hefei, Anhui 230001, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20180330
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5950531
OTO - NOTNLM
OT  - athymic nude mice
OT  - cell proliferation
OT  - cisplatin
OT  - gene expression
OT  - lung squamous cell carcinoma
OT  - patient-derived tumor xenograft
EDAT- 2018/05/29 06:00
MHDA- 2018/05/29 06:01
PMCR- 2018/03/30
CRDT- 2018/05/29 06:00
PHST- 2017/11/03 00:00 [received]
PHST- 2018/03/20 00:00 [accepted]
PHST- 2018/05/29 06:00 [entrez]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2018/05/29 06:01 [medline]
PHST- 2018/03/30 00:00 [pmc-release]
AID - OL-0-0-8401 [pii]
AID - 10.3892/ol.2018.8401 [doi]
PST - ppublish
SO  - Oncol Lett. 2018 Jun;15(6):8589-8603. doi: 10.3892/ol.2018.8401. Epub 2018 Mar 
      30.